WuXi Biologics (Cayman) Inc. (WXIBF)
OTCMKTS · Delayed Price · Currency is USD
5.20
0.00 (0.00%)
At close: Feb 11, 2026
WuXi Biologics Revenue
WuXi Biologics had revenue of 9.95B CNY in the half year ending June 30, 2025, with 17.21% growth. This brings the company's revenue in the last twelve months to 20.05B, up 17.16% year-over-year. In the year 2024, WuXi Biologics had annual revenue of 18.68B with 9.63% growth.
Revenue (ttm)
20.05B CNY
Revenue Growth
+17.16%
P/S Ratio
7.83
Revenue / Employee
1.60M CNY
Employees
12,552
Market Cap
21.91B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.68B | 1.64B | 9.63% |
| Dec 31, 2023 | 17.03B | 1.77B | 11.56% |
| Dec 31, 2022 | 15.27B | 4.98B | 48.38% |
| Dec 31, 2021 | 10.29B | 4.68B | 83.35% |
| Dec 31, 2020 | 5.61B | 1.63B | 40.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
WuXi Biologics News
- 1 day ago - WuXi Biologics earnings jump as ‘follow and win the molecule’ strategy pays off - South China Morning Post
- 1 day ago - Hong Kong stocks rise as positive holiday bias sets in ahead of Lunar New Year - South China Morning Post
- 3 days ago - WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally - PRNewsWire
- 14 days ago - WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody - PRNewsWire
- 16 days ago - HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline - PRNewsWire
- 4 weeks ago - JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth - PRNewsWire
- 4 weeks ago - WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha